Gilead Sciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
CEODaniel P. O'Day
CEODaniel P. O'Day
Employees17,600
Employees17,600
HeadquartersFoster City, California
HeadquartersFoster City, California
Founded1987
Founded1987
Employees17,600
Employees17,600
GILD Key Statistics
Market cap139.31B
Market cap139.31B
Price-Earnings ratio22.05
Price-Earnings ratio22.05
Dividend yield2.81%
Dividend yield2.81%
Average volume7.21M
Average volume7.21M
High today$112.65
High today$112.65
Low today$111.10
Low today$111.10
Open price$111.37
Open price$111.37
Volume6.54M
Volume6.54M
52 Week high$121.83
52 Week high$121.83
52 Week low$81.83
52 Week low$81.83
GILD News
TipRanks 2d
Buy Recommendation for Gilead Sciences Amid Strategic Positioning and Legal DevelopmentsAnalyst Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences and keeping the price target at $143.00. Elevate Your Investing Strategy: T...
Simply Wall St 3d
What Gilead Sciences's Global HIV Partnership and US Manufacturing Expansion Means for ShareholdersIn early September 2025, Gilead Sciences announced a partnership with the U.S. State Department and PEPFAR to expand access to its twice-yearly injectable HIV-1...
Simply Wall St 6d
Gilead Sciences Commits To Veeva Systems For Vault CRM Suiterecently announced that Gilead Sciences has committed to using its Veeva Vault CRM, highlighting the company's expansion in the pharmaceutical CRM space through...
Analyst ratings
70%
of 30 ratingsBuy
70%
Hold
30%
Sell
0%
People also own
Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.